Suppr超能文献

由原始 SARS-CoV-2 株诱导的抗体可中和 Alpha 至 Omicron BA.1 的变体。

Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1.

机构信息

Boston Children's Hospital, Boston, MA 02115, USA.

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Sci Immunol. 2022 Aug 12;7(74):eabo3425. doi: 10.1126/sciimmunol.abo3425.

Abstract

Neutralizing antibodies that recognize the SARS-CoV-2 spike glycoprotein are the principal host defense against viral invasion. Variants of SARS-CoV-2 bear mutations that allow escape from neutralization by many human antibodies, especially those in widely distributed ("public") classes. Identifying antibodies that neutralize these variants of concern and determining their prevalence are important goals for understanding immune protection. To determine the Delta and Omicron BA.1 variant specificity of B cell repertoires established by an initial Wuhan strain infection, we measured neutralization potencies of 73 antibodies from an unbiased survey of the early memory B cell response. Antibodies recognizing each of three previously defined epitopic regions on the spike receptor binding domain (RBD) varied in neutralization potency and variant-escape resistance. The ACE2 binding surface ("RBD-2") harbored the binding sites of neutralizing antibodies with the highest potency but with the greatest sensitivity to viral escape; two other epitopic regions on the RBD ("RBD-1" and "RBD-3") bound antibodies of more modest potency but greater breadth. The structures of several Fab:spike complexes that neutralized all five variants of concern tested, including one Fab each from the RBD-1, -2, and -3 clusters, illustrated the determinants of broad neutralization and showed that B cell repertoires can have specificities that avoid immune escape driven by public antibodies. The structure of the RBD-2 binding, broad neutralizer shows why it retains neutralizing activity for Omicron BA.1, unlike most others in the same public class. Our results correlate with real-world data on vaccine efficacy, which indicate mitigation of disease caused by Omicron BA.1.

摘要

中和抗体识别 SARS-CoV-2 的刺突糖蛋白,是宿主抵御病毒入侵的主要防线。SARS-CoV-2 的变体带有允许许多人类抗体(尤其是广泛分布的“公共”类抗体)逃避中和的突变。鉴定能够中和这些变体的抗体并确定其流行率,是了解免疫保护的重要目标。为了确定初始武汉株感染后 B 细胞库所产生的针对 Delta 和 Omicron BA.1 变体的特异性,我们测量了从早期记忆 B 细胞反应的无偏调查中获得的 73 种抗体的中和效力。针对刺突受体结合域(RBD)三个先前定义的表位区域的抗体,其中和效力和变体逃逸抗性各不相同。ACE2 结合表面(“RBD-2”)带有中和抗体的结合位点,其具有最高的效力,但对病毒逃逸的敏感性最大;RBD 上的另外两个表位区域(“RBD-1”和“RBD-3”)结合的抗体效力稍低,但广度更大。中和所有五种变体的 Fab:spike 复合物的结构,包括 RBD-1、-2 和 -3 簇中的每个 Fab,说明了广泛中和的决定因素,并表明 B 细胞库可以具有避免由公共抗体驱动的免疫逃逸的特异性。RBD-2 结合的广谱中和抗体的结构解释了为什么它保留了对 Omicron BA.1 的中和活性,而不是同一公共类中的大多数抗体。我们的结果与疫苗功效的真实世界数据相关,这些数据表明 Omicron BA.1 引起的疾病得到了缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddb0/9097876/157b745e7df8/sciimmunol.abo3425-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验